keyword
https://read.qxmd.com/read/38635934/randomized-phase-ii-study-of-gemcitabine-with-or-without-atr-inhibitor-berzosertib-in-platinum-resistant-ovarian-cancer-final-overall-survival-and-biomarker-analyses
#1
JOURNAL ARTICLE
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, Alexandre André B A da Costa, Doga Gulhan, Andrea E Wahner Hendrickson, Bose Kochupurakkal, David L Kolin, Elise C Kohn, Joyce F Liu, Richard T Penson, Elizabeth H Stover, Jennifer Curtis, Hannah Sawyer, Madeline Polak, Dipanjan Chowdhury, Alan D D'Andrea, Anniina Färkkilä, Geoffrey I Shapiro, Ursula A Matulonis
PURPOSE: The multicenter, open-label, randomized phase 2 NCI-9944 study (NCT02595892) demonstrated that addition of ATR inhibitor (ATRi) berzosertib to gemcitabine increased progression-free survival (PFS) compared to gemcitabine alone (hazard ratio [HR]=0.57, one-sided log-rank P = .044, which met the one-sided significance level of 0.1 used for sample size calculation). METHODS: We report here the final overall survival (OS) analysis and biomarker correlations (ATM expression by immunohistochemistry, mutational signature 3 and a genomic biomarker of replication stress) along with post-hoc exploratory analyses to adjust for crossover from gemcitabine to gemcitabine/berzosertib...
April 2024: JCO Precision Oncology
https://read.qxmd.com/read/38613733/the-molecular-landscape-of-gastric-cancers-for-novel-targeted-therapies-from-real-world-genomic-profiling
#2
JOURNAL ARTICLE
Hiroyuki Yamamoto, Hiroyuki Arai, Ritsuko Oikawa, Kumiko Umemoto, Hiroyuki Takeda, Takuro Mizukami, Yohei Kubota, Ayako Doi, Yoshiki Horie, Takashi Ogura, Naoki Izawa, Jay A Moore, Ethan S Sokol, Yu Sunakawa
BACKGROUND: Panel-based comprehensive genomic profiling is used in clinical practice worldwide; however, large real-world datasets of patients with advanced gastric cancer are not well known. OBJECTIVE: We investigated what differences exist in clinically relevant alterations for molecularly defined or age-stratified subgroups. METHODS: This was a collaborative biomarker study of a real-world dataset from comprehensive genomic profiling testing (Foundation Medicine, Inc...
April 13, 2024: Targeted Oncology
https://read.qxmd.com/read/38611095/safety-of-the-breast-cancer-adjuvant-radiotherapy-in-ataxia-telangiectasia-mutated-variant-carriers
#3
JOURNAL ARTICLE
Rayan Bensenane, Arnaud Beddok, Fabienne Lesueur, Alain Fourquet, Mathilde Warcoin, Marine Le Mentec, Eve Cavaciuti, Dorothée Le Gal, Séverine Eon-Marchais, Nadine Andrieu, Dominique Stoppa-Lyonnet, Youlia Kirova
The Ataxia-Telangiectasia Mutated (ATM) gene is implicated in DNA double-strand break repair. Controversies in clinical radiosensitivity remain known for monoallelic carriers of the ATM pathogenic variant (PV). An evaluation of the single-nucleotide polymorphism (SNP) rs1801516 (G-A) showed different results regarding late subcutaneous fibrosis after breast radiation therapy (RT). The main objective of this study was to evaluate acute and late toxicities in carriers of a rare ATM PV or predicted PV and in carriers of minor allele A of rs1801516 facing breast RT...
April 5, 2024: Cancers
https://read.qxmd.com/read/38608781/immunohistochemical-findings-and-clinicopathological-features-of-breast-cancers-with-pathogenic-germline-mutations-in-non-brca-genes
#4
JOURNAL ARTICLE
Kamaljeet Singh, Jennifer Scalia, Robert Legare, M Ruhul Quddus, C James Sung
Deleterious germline mutations in multiple genes confer an increased breast cancer (BC) risk. Immunohistochemical (IHC) expression of protein products of mutated high-risk genes has not been investigated in BC. We hypothesized that pathogenic mutations may lead to an abnormal IHC expression pattern in the tumor cells. BCs with deleterious germline mutations in CHEK2, ATM, PALB2 &PTEN were identified. Immunohistochemistry was performed using Dako staining platform on formalin fixed paraffin embedded tumor tissue...
April 10, 2024: Human Pathology
https://read.qxmd.com/read/38601449/-atm-the-gene-at-the-moment-in-non-small-cell-lung-cancer
#5
EDITORIAL
Kelsie L Thu, Ju-Yoon Yoon
No abstract text is available yet for this article.
March 29, 2024: Translational Lung Cancer Research
https://read.qxmd.com/read/38593799/dna-pk-and-atm-drive-phosphorylation-signatures-that-antagonistically-regulate-cytokine-responses-to-herpesvirus-infection-or-dna-damage
#6
JOURNAL ARTICLE
Joshua L Justice, Tavis J Reed, Brett Phelan, Todd M Greco, Josiah E Hutton, Ileana M Cristea
The DNA-dependent protein kinase, DNA-PK, is an essential regulator of DNA damage repair. DNA-PK-driven phosphorylation events and the activated DNA damage response (DDR) pathways are also components of antiviral intrinsic and innate immune responses. Yet, it is not clear whether and how the DNA-PK response differs between these two forms of nucleic acid stress-DNA damage and DNA virus infection. Here, we define DNA-PK substrates and the signature cellular phosphoproteome response to DNA damage or infection with the nuclear-replicating DNA herpesvirus, HSV-1...
April 2, 2024: Cell Systems
https://read.qxmd.com/read/38592373/targeting-smad3-improves-response-to-oxaliplatin-in-esophageal-adenocarcinoma-models-by-impeding-dna-repair
#7
JOURNAL ARTICLE
Farah Ballout, Heng Lu, Nadeem Bhat, Lei Chen, Dunfa Peng, Zheng Chen, Steven Chen, Xiaodian Sun, Silvia Giordano, Simona Corso, Alexander Zaika, Oliver McDonald, Alan S Livingstone, Wael El-Rifai
PURPOSE: TGFβ signaling is implicated in the progression of most cancers, including esophageal adenocarcinoma (EAC). Emerging evidence indicates that TGFβ signaling is a key factor in the development of resistance toward cancer therapy. EXPERIMENTAL DESIGN: In this study, we developed patient-derived organoids and patient-derived xenograft models of EAC and performed bioinformatics analysis combined with functional genetics to investigate the role of SMAD family member 3 (SMAD3) in EAC resistance to oxaliplatin...
April 9, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38577344/case-report-and-literature-review-of-rezvilutamide-in-the-treatment-of-hormone-sensitive-prostate-cancer
#8
Chunlei Zhang, Jie Ren, Yindong Kang, Dehui Chang
BACKGROUND: Prostate cancer represents a major health concern worldwide, with the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and locally advanced prostate cancer posing a particular challenge. Rezvilutamide, a new androgen receptor antagonist from China, has shown early promise; however, its real-world effectiveness and safety profile require further evidence. This case series evaluates the preliminary clinical outcomes of rezvilutamide in combination with androgen deprivation therapy (ADT), focusing on PSA response and radiological findings across various stages of prostate cancer in four patients...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38567167/synchronous-papillary-thyroid-cancer-and-colorectal-cancer-in-a-young-patient-with-a-chek2-mutation
#9
Sydney Brooke Hoskins, Leslie Torgerson
INTRODUCTION: Mutations of CHEK2 are usually inherited and have been implicated in breast cancers, colorectal cancers, thyroid cancers, kidney cancers, and prostate cancers. The CHEK2 gene codes for checkpoint kinase 2 protein which is an effector in the ATM-CHEK2-p53 pathway and responds to DNA double-strand breaks. CASE PRESENTATION: We describe a unique case of a 29-year-old Canadian female who presented with synchronous papillary thyroid carcinoma and rectal adenocarcinoma who was subsequently found to have a sporadic CHEK2 (checkpoint kinase 2) mutation...
2024: Case Reports in Oncology
https://read.qxmd.com/read/38561609/the-neem-limonoid-nimbolide-modulates-key-components-of-the-dna-damage-response-signalling-in-cellular-and-animal-models-of-oral-squamous-cell-carcinoma
#10
JOURNAL ARTICLE
Soundararajan Arvindh, Manashi Priyadarshini, Abdul Basit Baba, Veeran Veeravarmal, Rajakishore Mishra, Rupesh Dash, Siddavaram Nagini
BACKGROUND: A deregulated DNA damage response (DDR) network is implicated in cancer progression and therapy resistance. OBJECTIVE: The present study was designed to investigate whether nimbolide, an anticancer neem limonoid, targets key components of the DDR signalling pathway in cellular and animal models of oral squamous cell carcinoma (OSCC). METHODS: OSCC cells (SCC-4 and SCC-9), 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster buccal pouch (HBP) carcinoma model, chemoresistant OSCC patient-derived xenograft (PDX) model established in athymic nude mice, and tissue sections from patients with oral premalignant/malignant disease were used for the study...
March 28, 2024: Current Pharmaceutical Biotechnology
https://read.qxmd.com/read/38561595/dna-damage-driven-inflammatory-cytokines-reprogramming-of-tumor-immune-microenvironment-and-application-of-oncotherapy
#11
REVIEW
Meng-Jie Wang, Yu Xia, Qing-Lei Gao
DNA damage occurs across tumorigenesis and tumor development. Tumor intrinsic DNA damage can not only increase the risk of mutations responsible for tumor generation but also initiate a cellular stress response to orchestrate the tumor immune microenvironment (TIME) and dominate tumor progression. Accumulating evidence documents that multiple signaling pathways, including cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) and ataxia telangiectasia-mutated protein/ataxia telangiectasia and Rad3-related protein (ATM/ATR), are activated downstream of DNA damage and they are associated with the secretion of diverse cytokines...
April 2, 2024: Current Medical Science
https://read.qxmd.com/read/38554444/harmine-alleviated-stz-induced-rat-diabetic-nephropathy-a-potential-role-via-regulating-ampk-nrf2-pathway-and-deactivating-ataxia-telangiectasia-mutated-atm-signaling
#12
JOURNAL ARTICLE
Manar Mohammed El Tabaa, Maram Mohammed El Tabaa, Eman Rashad, Mohammed Salah Elballal, Ola Elazazy
Diabetic nephropathy (DN) is a serious kidney disorder driven by diabetes and affects people all over the world. One of the mechanisms promoting NF-κB-induced renal inflammation and injury has been theorized to be ATM signaling. On the other hand, AMPK, which can be activated by the naturally occurring alkaloid harmine (HAR), has been proposed to stop that action. As a result, the goal of this study was to evaluate the therapeutic effectiveness of HAR against streptozotocin (STZ)-induced DN in rats through AMPK-mediated inactivation of ATM pathways...
March 29, 2024: International Immunopharmacology
https://read.qxmd.com/read/38554309/depletion-of-cnot4-modulates-the-dna-damage-responses-following-ionizing-radiation-ir
#13
JOURNAL ARTICLE
Samira Eskandarian, Roger J Grand, Shiva Irani, Mohsen Saeedi, Reza Mirfakhraie
BACKGROUND: The Ccr4-Not complex (CNOT complex in mammals) is a unique and highly conserved complex with numerous cellular functions. Until now, there has been relatively little known about the importance of the CNOT complex subunits in the DNA damage response (DDR) in mammalian cells. CNOT4 is a subunit of the complex with E3 ubiquitin ligase activity that interacts transiently with the CNOT1 subunit. Here, we attempt to investigate the role of human CNOT4 subunit in the DDR in human cells...
January 1, 2024: Journal of Cancer Research and Therapeutics
https://read.qxmd.com/read/38551807/genomic-determinants-of-response-and-resistance-to-inotuzumab-ozogamicin-in-b-cell-all
#14
JOURNAL ARTICLE
Yaqi Zhao, Nicholas J Short, Hagop M Kantarjian, Ti-Cheng Chang, Pankaj S Ghate, Chunxu Qu, Walid Macaron, Nitin Jain, Beenu Thakral, Aaron Phillips, Joseph D Khoury, Guillermo Garcia-Manero, Wenchao Zhang, Yiping Fan, Hui Yang, Rebecca Garris, Lewis Fady Nasr, Richard Kriwacki, Kathryn G Roberts, Marina Y Konopleva, Elias J Jabbour, Charles G Mullighan
Inotuzumab ozogamicin (InO) is an antibody-drug conjugate that delivers calicheamicin to CD22-expressing cells. In a retrospective cohort of InO-treated patients with B-cell acute lymphoblastic leukemia, we sought to understand the genomic determinants of response and resistance to InO. Pre- and post-InO patient samples were analyzed by whole genome, exome, and/or transcriptome sequencing. Acquired CD22 mutations were observed in 11% (3/27) of post-InO relapsed tumor samples, but not in refractory samples (0/16)...
March 29, 2024: Blood
https://read.qxmd.com/read/38551383/ngs-of-brush-cytology-samples-improves-the-detection-of-high-grade-dysplasia-and-cholangiocarcinoma-in-patients-with-primary-sclerosing-cholangitis-a-retrospective-and-prospective-study
#15
JOURNAL ARTICLE
Sonja Boyd, Taru Mustamäki, Nelli Sjöblom, Arno Nordin, Andrea Tenca, Kalle Jokelainen, Tommi Rantapero, Thomas Liuksiala, Laura Lahtinen, Teijo Kuopio, Soili Kytölä, Heikki Mäkisalo, Martti Färkkilä, Johanna Arola
BACKGROUND: Biliary dysplasia, a precursor of cholangiocarcinoma (CCA), is a common complication of primary sclerosing cholangitis. Patients with high-grade dysplasia (HGD) or early CCA who have received oncological treatment are candidates for liver transplantation. The preoperative diagnosis of CCA or HGD is challenging, and the sensitivity of biliary brush cytology (BC) is limited. METHODS: By using next-generation sequencing (NGS), we retrospectively analyzed archived tissue samples (n=62) obtained from explanted liver tissue and CCA samples to identify oncogenic mutations that occur during primary sclerosing cholangitis carcinogenesis...
April 1, 2024: Hepatology Communications
https://read.qxmd.com/read/38542259/undifferentiated-carcinoma-with-osteoclast-like-giant-cells-of-the-pancreas-molecular-genetic-analysis-of-13-cases
#16
JOURNAL ARTICLE
Jan Hrudka, Markéta Kalinová, Vanda Ciprová, Jana Moravcová, Radim Dvořák, Radoslav Matěj
Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC) of the pancreas is a rare malignancy regarded as a subvariant of pancreatic ductal carcinoma (PDAC) characterized by variable prognosis. UCOGC shows a strikingly similar spectrum of oncogenic DNA mutations to PDAC. In the current work, we analyzed the landscape of somatic mutations in a set of 13 UCOGC cases via next-generation sequencing (NGS). We detected a spectrum of pathogenic or likely pathogenic mutations similar to those observed in PDAC following previously published results (10 KRAS , 9 TP53 , 4 CDKN2A , and 1 SMAD4 , CIC , GNAS , APC , ATM , NF1 , FBXW7 , ATR , and FGFR3 )...
March 14, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38539485/characterization-of-incidental-pathogenic-germline-findings-detected-via-ctdna-among-patients-with-non-small-cell-lung-cancer-in-a-predominantly-hispanic-latinx-population
#17
JOURNAL ARTICLE
Esha Vallabhaneni, Samuel A Kareff, Reagan M Barnett, Leylah M Drusbosky, Shivani Dalal, Luis E Raez, Edgardo S Santos, Federico Albrecht, Mike Cusnir, Estelamari Rodriguez
Pathogenic germline variants (PGVs) may be under-detected as causative etiologies in patients with non-small cell lung cancer (NSCLC). The prevalence of PGVs has been reported between 1 and 15% of patients, depending on the patient population. The rate within Hispanic/Latinx populations remains unknown. We retrospectively analyzed the genomic results (Guardant360, Redwood City, CA, USA) of 878 patients with advanced or metastatic NSCLC at five centers in South Florida, USA, from 2019 to 2022 to analyze the rate of incidental PGVs (iPGVs) identified via circulating cell-free tumor DNA (ctDNA)...
March 14, 2024: Cancers
https://read.qxmd.com/read/38538001/therapeutic-options-targeting-the-ataxia-telangiectasia-mutated-atm-mediated-dna-damage-response-macropinocytosis-and-adaptive-immunity-in-ovarian-cancer
#18
REVIEW
Cai-Chieh Tseng, Min-Hsi Ku, Yun-Chieh Wu, Wei-Lun Huang, Wei-Ming Wu, Ching Hua Pai, Chi-Wei Chen
Ataxia-telangiectasia mutated (ATM) is a pivotal protein with versatile kinase activity that responds to DNA damage. While its well-established role as a DNA repair protein is widely recognized, the understanding of its noncanonical functions in ovarian cancer remains limited. Numerous studies have investigated the potential of targeting ATM for ovarian cancer treatment. In addition to its involvement in homologous recombination repair (HRR), an increasing body of research suggests that ATM plays a role in cellular metabolism and adaptive immunity...
April 2024: Anticancer Research
https://read.qxmd.com/read/38533616/the-one-carbon-metabolic-enzyme-mthfd2-promotes-resection-and-homologous-recombination-after-ionizing-radiation
#19
JOURNAL ARTICLE
Petra Marttila, Nadilly Bonagas, Christina Chalkiadaki, Hannah Stigsdotter, Korbinian Schelzig, Jianyu Shen, Crystal M Farhat, Amber Hondema, Julian Albers, Elisée Wiita, Azita Rasti, Ulrika Warpman Berglund, Ana Slipicevic, Oliver Mortusewicz, Thomas Helleday
The one-carbon metabolism enzyme bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase 2 (MTHFD2) is among the most overexpressed proteins across tumors and is widely recognized as a promising anticancer target. While MTHFD2 is mainly described as a mitochondrial protein, a new nuclear function is emerging. Here, we observe that nuclear MTHFD2 protein levels and association with chromatin increase following ionizing radiation (IR) in an ataxia telangiectasia mutated (ATM)- and DNA-dependent protein kinase (DNA-PK)-dependent manner...
March 27, 2024: Molecular Oncology
https://read.qxmd.com/read/38530432/chemotherapy-initiated-cysteine-rich-protein-61-decreases-acute-b-lymphoblastic-leukemia-chemosensitivity
#20
JOURNAL ARTICLE
Pengchong Shi, Zhen Lin, Yanfang Song, Zhaozhong Li, Menglu Zeng, Li Luo, Yingping Cao, Xianjin Zhu
PURPOSE: Chemoresistance is a major challenge for acute lymphoblastic leukemia (ALL) treatment. Cysteine-rich protein 61 (Cyr61) plays an important role in drug resistance modulation of tumor cells, and Cyr61 levels are increased in the bone marrow of patients with ALL and contribute to ALL cell survival. However, the effect of Cyr61 on B cell acute lymphoblastic leukemia (B-ALL) cell chemosensitivity and the regulatory mechanisms underlying Cyr61 production in bone marrow remain unknown...
March 26, 2024: Journal of Cancer Research and Clinical Oncology
keyword
keyword
102390
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.